Study #2020-0793
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Vinorelbine, Actinomycin D, Vincristine, Cyclophosphamide Pill
Description
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Rhabdomyosarcoma
Study phase:
Phase II
Physician name:
Jonathan Gill
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.